For my ongoing education, must a Company only make an announcement PRIOR to the opening bell?
Printable View
If PEB had posted it at 3.30 in the afternoon would it be expected that NZX cancel all trades for the day, or the day before as well perhaps.
We have had many instances of announcements after opening by PEB, midmorning and afternoon
BLT is different in the announcement in the paper on Sunday preceded the sharemarket and it should have been available to the market prior to opening. It was not therefore there is a problem
Not in the same boat, IMHO:)
Nice of Kaiser to help PEB do a bigger and more statistical significant trial.
Obviously Kaiser are not so skeptical of the benefits of CxBladder that they are rejecting it outright.
Wonder whether PEB have to pay Kaisers administration fees for this !
So is this N thousand unpaid tests?
And presumably no paid tests via Kaiser until 2015 if then ?
Still a very speculative stock and thus:
Increased SP = Increased risk.
Best Wishes
Paper Tger
Hmmmm. Interesting! Kaiser Permanente seed funded the development of Predictive Biosciences CertnDx.
Cheers
Miner:)
This is massive News! Yes, no sales. But the opportunity to prove your product can improve the current testing situation, reduce liability to urologists, save life's, and set a standard other insurers have to match!
I have no idea how this news should affect the short term share price.
This is a toe in the door, if you don't value this information. I would question your business knowledge and experience.
The results will come out "early 2015", this will be reputable proof of how well cxbladder can detect bladder cancer! A USA leading company doing an impartial trial! They're recruiting 2000 people by the looks of it, PEB only used 485 in their trials. Assuming this comes back with similar results, I think it will be fantastic! Very good news.
Absolutely! Look how RAK has jumped over the last month.Quote:
Originally Posted by MAC
This could be really good!?
Yep, it all adds further clarity to the forward revenue schedule too;
>>> Network providers go first, Pacific Edge have told us it takes effectively seven months from sign up to commercial sales commencing. Of the four signed up thus far, the first (FedMed) was signed up in October last year, the latest (Multiplan) in May this year.
>>> Medicare sales have been occurring for over a year now and Pacific Edge have told us that those revenues are being held by Medicare awaiting release upon contract signing, maybe before the end of this reporting period on 30th September, maybe after.
>>> And now we see the start of HMO sign up's with what seems like around about a nine month lead from user programme commencement to effective commercial clinical sales accumulating.
A few overlapping timelines can start to add up.
Kicking some numbers around, that prospective Kaiser Permanente contract could alone be worth US$10 to US$20M per annum in revenues.
I just had a thought... I am pretty sure that in the last year that I recall seeing some news from PEB about how they have further increased the accuracy of their test, as that is one thing that they want to do -- seems entirely prudent.
Is it therefore likely that we should see an even better result from this Kaiser user program than the initial one?
EXPOSER--Its about exposer--I spent alot of time looking for a sign that PEB was even mentioned in the US medical community--This is a step in the right direction for recognition.
That was my biggest concern -marketing recognition.
To me thats more important than sales at this stage. (It shows that the marketing team are out there doing their job)
I dont think there are many who doubt that it will be successful in the testing--Its kind of like saying -''ok we see youve got this product,lets give it a go and see if its worth its salt''
Imo it was worth the rise in SP
Where the hell is this Edison report?
See what's happened to SCY shareprice when Edison come out with a hyped up valuation
Jeez PEB valued at $1.40 to $1.70 by Edison would see shareprice rocket over the $1 mark
Might need to adjust my 90/100 short term target
C'mon Edison ...hurry up with that report
Here's a hypothetical question. Say if revenue reaches $100m and PEB starts making a profit, how much would the company be worth?
I love it how everybody throws numbers around like PEB has already achieved everything they set out to do.. Let's not forget about what this stock is about. Diagnosis of cancer.... yes we can all have our dreams about the share price but how many people here would give their shares back just to see a loved one taken by the bloody thing in the past? All the best to PEB and those involved, let's not forget them in all the profit speak.
I think that is a given benjitara. This is not a tobacco stock or alcohol stock. PEB is in the business of saving lives, not destroying them. As shareholders we know this. I see nothing callous in profit projections for this stock because greater profits mean more people are accessing a superior diagnostic tool, enhancing their health outcomes.
My conservative take on it - also 'back of the envelope'
$80m Gross profit
Fiixed costs higher, say $30m
Net $50m
$50m / 318m shares = 16cps
payment / nominal rate = price Lets be conservative (in this case greedy) and not invest unless they paid a 10% divvy
0.16 / 0.1 = $1.6 per share in 5 years time
To discount that price to todays present value, use 10%. Why only 10%? It includes no default premium because you either believe it's going to happen or you don't. If it fails, discounting by an extra 3% is hardly going to save your bacon.
So FV $1.60 / (1.1^5) = near enough to $1PV
There you have it, $1 conservatively if they're going to make it
Summary, if you believe PEB are going to crack 10% and get the $100m then you can pay $1 now and effectively earn 10% from now until they stop, PEB can spend $30m a year against the $100m and don't have to develop anything else....
You just have to decide if they're going to crack it......
NBT - they might be paying tax by then
[QUOTE=nextbigthing;501232]
With so much Info... Talk and Speculation with this stock..
I think that you have summed it up well ..
" You just have to decide if they're going to crack it "
Win some lose some...
Disc... Holding ... Minor..
If the results do come back from this larger study better than the O’Sullivan et al study.. even by just a few percentage points (like the results yielded by the combined study done by Canterbury and Waitemata DHBs where cxBladder detected 90% of all BC) we start getting into interesting territory.
Fairly sure the latest cystoscopy tech has a sensitivity of around 92-95%.
Cystoscopy's first weakness is finding small "in situ" cancers which are generally early stage.
Its second weakness is that it doesn't find cancer in the upper urinary tract. Which as we know, cxBladder can do.
Imagine a study done by medical insurer Kaiser Permanente, on 2000 patients where cxBladder outperformed cystoscopy.
I bought one of these years ago, absolutely invaluable at the time, a recommend a read for just $17.
http://www.amazon.com/Fundamental-An...J269Z6R4YM4FQE
My post is merely running some numbers to see if they stack up and very conservatively at that. Non industry specific.
I absolutely agree that PEB has massive potential especially if they crack one product, then they'll be away. Those numbers are worst case scenario if they do crack it.
So there's a chance they will be worth over $1b one day? I'm looking to invest in companies that are worth around $250m today but has the potential to be a billion dollar company. Anything else on nzx in that category?
Has anyone any ideas as to the cost of this user programme?
I'm thinking its in the millions,
It's a 2,000 test at 19% COGS: 2,000 x 550 x 0.19 = US$209k = loose change
Think of it as a marketing budget except with much much better odds of success in leading to what is probably a greater than US$10M per annum contract.
Just one large contract like that, or two smaller ones, secured each year, plus Medicare sales, plus LUG sales, and it put’s that US$100M five year revenue goal into perspective.
Personally I think the risk of prosperity and that goal are both a bit understated.
http://www.youtube.com/watch?v=mv2JDCKLi0k
Best Wishes
Paper Tiger
Sorry I'm not 100% on which bit you're unsure of? I'm not trying to claim PEB will trade at a PE of 10 or that it should. Simply that if you believe their target will happen then even at $1 you can't go wrong as shown by the numbers with anything else all being upside. Hope that makes sense.
I recall a slide from a peb presentation, it showed the test being used multiple times when first diagnosed (maybe up to eight times.)
8 x 2000 =16000
16000 tests to show off the cx product at a cost of 1-2mill????
Again not big dollars, and the opportunity is endless. But it will add to the expenses and its useful to have an understanding of these costs.
http://www.odt.co.nz/news/business/3...e-pacific-edge
Nothing new in this article, but just posting so people are aware.
Hope today sees another push towards 90 cents ....and then onto a$1.00
Where the hells that Edison Report.
Smiths City earlier in the week and now Tourism Holdings .... both valuations much higher than current shareprice
C'mon guys pull finger .... PEB needs a boost quickly if to get to $1 in September
And we have heard it is $1.40 to $1.70
Short termers are loving it...
Whilst looking for something else, I stumbled upon some information about the cxbladder test which were of interest to me:
http://www.healthscopepathology.com....ogy/cxbladder/
There's a link to a brochure and clinical validation overview on the left.
From the announcement;
“The Kaiser Permanente User Program research project is planned to recruit approximately 2000 patients presenting with microscopic and macroscopic hematuria (blood in the urine), from the 3.7 million members of Kaiser Permanente Southern California.”
No, definitely not millions of dollars, just a couple of hundred thousand, the “2,000 patients” are not ‘cancer patients’, they are ‘haematuria patients’, thus requiring preliminary screening rather than work-up tests.
It's possible but unlikely that most would get tested twice within that six month duration, perhaps some of those tested close to the commencement of the programme may though, depends what’s been agreed.
Pacific Edge described it as being similar to the Mid Central Heath user programme, so we should also expect PEDusa to similarly pick up the tab.
Both user programmes are more a commercial evaluation than a clinical evaluation.
“Cxbladder is currently being evaluated in New Zealand for a similar clinical value proposition by Mid-Central District Health Board in Palmerston North. The commercial evaluation by Mid-Central DHB is to establish the levels of patient benefits and savings that can be achieved from the use of Cxbladder in a similar clinical setting to Kaiser Permanente by ruling out patients referred with micro-haematuria who do not have bladder cancer.”
Unfortunately snapiti, I think your right, Nz Clinicians are worried more about how much CX bladder costs and how it won't fit their budgets.
But in the states, if a urologists mistake allows a person to die, they and their practice could be liable for massive lawsuits. Especially when you have a reliable product like Cxbladder that could have picked up what they missed.
Americans don't like to be sued, hence the cx bladder market. Kiwi urologists don't have that pressure and unfortunately the condition of some of the medical boards in new Zealand is simple distributing.
This opportunity is much bigger than anything NZ could offer.
Just having a breather at the end of week
Up 12 cents since fiasco of the ASM and up 9 cents this week so all positive
More impetus in this rise from below 70 cents which suggests a lot more support now
That 110 mark on the chart looks a good target - was looking at 100 but I think I'll aim for the 110, by end of September
Next week another 9 cents will be fine
I have no idea of the American law system. But I know Americans, and if somebody dies when it was easily preventable (like pissing in a cup). Then change will be forced, all it takes is this user programme to highlight a few American urologists mistakes and they will conform, Completely agree, positive sales figures are a long way away. But I see this company being a lot bigger than one product.
Lets just all keep our feet on the ground--we dont need to get into ''hype'' territory again.
Slow steady growth will do just fine.
Seems that it’s all going pretty much to plan as it was all laid out.
Four network providers signed up thus far, the first HMO negotiation concluding with KP and an associated user programme ready to go, preliminary negotiations with Medicare made whom have been accruing revenues for Pacific Edge for a year or so now.
So, they are ahead with signing up network providers, about roughly on track with KP or within a few months at least, and may probably be a little ahead with Medicare and Medicaid negotiations.
Pacific Edge are doing a damn fine job IMHO.
From the October 2013 capital raising:
Pacific Edge is targeting large, integrated healthcare providers (such as Kaiser Permanente and Intermountain) where the insurance, hospital and medical group functions are fully integrated with a focus on best, most cost effective clinical outcome for members.
• Kaiser Permanente, for example, has 8.9 million members2
• These integrated healthcare providers are targeted to be strategic partners for Pacific Edge – discussions have commenced between Pacific Edge and various integrated healthcare providers, however it is anticipated that negotiations could take 12 months
Building a relationship with the CMS is a key target for Pacific Edge (CMS is the US federal agency which administers Medicare and Medicaid and will reimburse Pacific Edge for all Medicare / Medicaid patients who utilise Cxbladder)
• Pacific Edge anticipates continuing and concluding negotiations in earnest with Medicare and Medicaid in 2014. Pacific Edge has already conducted preliminary discussions with these entities.
• Approximately 115 million U.S. citizens are covered by Medicare and Medicaid
Regarding the Kaiser user programme, they are testing people with hematuria right? 2000 thousand people...
From memory the bladder cancer rate for people with hematuria is 5-6%, so expect 100-150 people to actually have bladder cancer. It is these people that will be monitored using CxBladder after detecting their bladder cancer and during/after having it dealt with. So recurring test likely won't be on the 2000, but will be on the 100-150. That is the 2 million tests they are targeting, recurring tests of patients that have had cancer.
Another interesting thing will be to see how long the user programme is. It could quite feasibly be a year or longer if they are doing a full test of the system including detecting reoccurance. I also assume they will be doing the programme side by side with current treatment methods, but where are they doing the actual tests within the process? I remember PEB released a flow chart of the current treatment plan for patients presenting with hematuria moving through to bladder cancer. They had added where CxBladder could be used in the process, are they testing each of these points with the user programme? If not, which ones? Hopefully they will release a plan for the user programme we can see...
My notebook says there were 74,000 new cases of bladder cancer in 2013 from around about 2 million presentations of haematuria, so yep around 3.7% will have cancer. So thus 74 may require a further work-up.
The user programme though is only six months in duration, long enough to process and screen test 2,000 haematuria patients against the performance of cytology, maybe long enough to further test the 74 I don’t know, probably, possibly.
I agree it would make some sense for KP to want to try and work through all the value propositions, for the 74 patients, I’m just not sure that can be done within a six month duration.
Hancock’s might have a better feel for that.
It would take an insider to be sure wouldn't it Moosie, but there are some things we've been advised of.
Pacific Edge have been in talks with KP since late last year, my expectation would be that the eight value propositions have been quite well discussed and understood, and it is fair that KP should wish to trial new internal processes along with new diagnostic test providers before a final commitment to terms for which will probably be a long term contract.
Pacific Edge in the announcement said that the user programme would run from late this year into early 2015.
Because a lot of probably both commercial and clinical discussion has already been had, we may see a roll over quite soon after.
I'm supportive of Pacific Edge taking as long as is needed though to get it right, especially for the first HMO in the queue. There’s no point rushing in for a terms worse than they could have got. It's better that it takes as long as it takes.
I'm quite content with this whole user programme strategy actually, lot's more to come, let's see.
I'm not sure this is completely correct, I think a urologist has to use all reasonable means to correctly diagnose cancer. Pathways are used as guides for practitioners, if a patient suspects a practitioner ignored modern means of diagnostic a malpractice case could be formed. Remember most malpractice law suits fail, its not only the payout that's expensive, its the defence. Yes their insurance will financially protect them, but lose of face, damage to their practice, poor reputation, on-going losses is not compensated. Its in the urologists best interests to use the most modern forms of diagnostics.
Pathways will change after time, after lawsuits, after deaths, you might be waiting sometime for cxbladder to be installed in a pathway. I expect sales to have progressed well before this point.
Again targeting insures is the key, they are doing this.
This company needs investor support, and a lot of patience.
I think Profitability is a long way off.
It would be a few years down the road if it all but:
Potential 'universal' blood test for cancer discovered
Best Wishes
Paper Tiger
Well timed post PT..
Shareholders have to keep reminding themselves that PEB is operating in the Bio Techology sector that is heavily affected by the current Industrial Revolution (IR)...
With IR new and innovative change takes hold and develops at an exponential pace causing recent events to be quickly outdated at an accelerating pace
Companies have to continuously adapt or perish...Is PEB able to do this??..
Disc: I'm a recent "large";) investor
The question is - will it be able to determine the location of the cancer? I highly doubt analysing the white blood cell damage with UV light will be able to determine the location of the cancer. Of course the patients symptoms may provide some clues but often patients do not present symptoms until later stages. I lost my mother to cancer 6 years ago - and the doctors never located the primary tumour, only secondaries (she used public and private hospitals with numerous scans). This meant operating would only be a short term band-aid and would only hinder the quality of her remaining life - unless they were able to locate and remove the primary tumour. So in the context of this new technology - knowing that cancer is present or forthcoming is one thing, but will they need products such as CXbladder to determine the location?
I would imagine that Jackie and her team must be pretty well versed in all this stuff, and it would be traversed extensively whenever they go out to talk to urologists or their insurers and others involved.
I admire the amount of research some on this thread have been putting in, but wonder how much point there is in trying to second-guess the urologists, lawyers and over-arching user groups in USA from this distance. It seems to me that it could be useful to put some questions to DD on this and ask him to answer them through one of the media pieces or briefings he sometimes does. It's obviously got to be part of the CxB sales pitch.
DD does like to tell the story, which is just as well I’ve always thought as there’s a lot of it. The double shot’s a good ‘you beaut’ summary NT, October last year but all good. About time for another one perhaps ?
https://www.youtube.com/watch?v=BE43Of1TUGY
I thought Robbo's question was justified? Tho he might need to work on his politeness,
Evidence to back up your statement would be useful.
My very limited experience with dealing with insurers is they are very accommodating.
When I need to makes changes to my public, product or personal insurance, they just want to know what and when your doing unusually activities.
I know this is a apples and oranges situation and my mare ten million dollar package is a drop in the ocean compared to a LUG. I'd be very surprised if an insurance company was willing to loose a client over the use of a complimentary testing product. I'm sure they would be willing to make amendments to policies for LUG.
Is anyone keeping an active eye on the competition?
I see a massive company called Abbott supplying the Fish and complementary Uri Vysion test, as pretty bloody serious, I believe they have started their own 1200 patient user programme, I've so far listed eight companies who have a bladder cancer testing product, any ideas how to best track these products without loosing my life?
THIS is what concerns me.
PEB may have a 'best in class' product however when it comes to commercialization they are up against some heavy competition that have a lot of money to burn on marketing.
Personally for me I would like to see some more clarity around their sales numbers (e.g. quarterly sales updates). My concern is that if they can't get traction early on then when will they? Their cash stocks can only hold out for so long and it may take a while for market acceptance.
On the flip-side, US $100m revenue in five years IS achievable (as demonstrated by some of their peers) however its this first year which is crucial to gain traction in.
DISC: watching like a hawk on the side-lines.
It been 6 months since it crossed the MACD base line so thats a bonus! I think .........
Its been 6 months since is crossed the MACD LINE upwards , so that's hopeful..... Lets see how far it goes .....
My Dad was a pilot, would you like to fly in a plane with me on the back of that information?
I am in the insurance game. I think your suggestions about the content of medical professional liability insurance is the product of your imagination with a hint of dramatised US television to add spice.
By all means, post the policy wording you refer to.
Yes MAC, I think it would be just great if DD could do another interview like this, but get it done in-house for the PEB website, explaining where the technology is at now and the nature of the multi-faceted task facing the marketing team. Also perhaps mentioning the two new products in the portfolio that must be just about ready now. It wouldn't be hard for a good PR company to set this up, with a professional interviewer properly briefed with some hard questions that our members could provide. It mustn't just be soft-soap, and should have input from Jackie's team as well.
It could even serve as a useful adjunct for the marketing team - something that potential clients could find on the site, including those outside the areas being covered by the team at present. The first video is great as an introduction to the underlying science, and DD is an excellent communicator. The second could follow on from it, and could demonstrate that PEB understands the full range of clinical and professional issues faced by a practitioner in deciding whether it would be safe, practical, ethical and economical to switch to CxB. And to the patient's benefit.
Yep, another would be a good thing esp for those who don’t have the idle time some of us do and just want a summary.
I think perhaps we may all have just got that at the AGM though, it was a shame I would agree that the video recording didn't work, perhaps if enough folk make a request on that basis another double shot might follow, who knows.
The close work they have done with clinicians, the development of the quite specific value propositions (clinical and commercial) and the marketing strategy they have adopted all speaks for itself quite thoroughly though really.
I was definitely NOT suggesting that a David Darling video should attempt to give more detailed or frequent financial information. My concern is that some members of this thread seem to spend a lot of time trying to speculate on issues such as whether US urologists will be deterred from adopting CxB by such factors as collegial rules, traditional diagnostic training, Cancer Network guidance, professional liability insurance contracts, legal pressures and concerns about competing new techologies offered by US pharma.
Some aspects of the marketing campaign were apparently touched on in the Q&A section of the ASM but not in detail and apparently no record was kept when the video transmission fiasco occurred.
There now appears to be a concern/assumption among some on this thread that PEB may not have much of a clue what it is doing now that it has moved into the marketing and commercialisation phase in the USA, a market renowned for its multi-layered regulatory environment, its enormously powerful pharmaceutical corporations and its penchant for medical litigation. I'm not saying that perception is widespread, but it's been coming through strongly in some rather acrimonious postings.
PEB is not quite your typical NZSX company. As DD has said, it's almost like a family firm. Many of those with shares care deeply about it, have faith in it. I'm one of those. Recently the company showed excellent initiative by bringing the head of its US marketing team to NZ and arranging for its ASM to be webcast. Total disaster, as we all know. But worse still, the disaster continues because of the information vacuum that continues as regards the marketing strategy and campaign. Information vacuums allow incorrect and negative perceptions to become deeply embedded.
I agree with those who suggest PEB is already issuing enough financial information. Providing more would probably only help CxB's competitors, and the traders. But I would like DD, who is an excellent communicator, to arrange for a follow-up to the video he did with interest.co.nz just under a year ago. That first video covered the early scientific phase of the company's operations. Now it's time to describe how CxB is being marketed - the strategy, and the reactions it's getting. The hoops PEB has to jump through, both with the regulators and in persuading urologists and others in the US why they should adopt a test developed in far-off NZ, and what's in it for them and their patients. No big secrets, nothing share-price sensitive. Just someting to fill the information gap that at present is engendering negativity and fear within the "family firm". I plan to suggest this to DD.
Yep, I'd agree with all that.
Although, those you refer to are largely just knockers knocking, they don’t have any real genuine interest or concern for that matter, they just get their jollies by making up area 51 conspiracies and attempting to scare newbies, just pathetic and lame to everyone else really.
NT, have you got all the commercialisation presentations, and the 2011 and 2013 capital raising docs, etc, ?
Ok, so a serious answer is fair then, I do Moosie, you may have seen my SUM exit play out a few months ago after having been a happy holder for over two years.
I don't re-balance a lot at all really, increasingly less has proved more prosperous for me over the years, although it does take balls of steel at times, I’ve made just five buys and sells in the last twelve months, two of which were rights issues.
My exit strategy for Pacific Edge is similar to most of my growth portfolio holdings, any of which would see me sell;
a) Growth plateauing (it's just the beginning though for Pacific Edge)
b) On notice after a first dividend announcement
c) The end of the bull cycle (I do a lot of FA work on this per the other thread)
d) A fundamental shift in the underlying efficacy of the company (watching all the time)
So with 2 months to go what is everyones expectations for the next financial results? I note that the new NXT market requirement to have quarterly updates and havent seen any financial/performance metrics from PEB for a few months. For followers of this stock do PEB release quarterly updates and if not why does the NXT require them but not NZX main?
Oh well in that case I suppose everyone can take your word for it that: (1) Insurance policies say what you say they say, and; (2) They are impossible to obtain because you say so, and; (3) Your Dad is an insurance expert therefore your vaguely scrawled opinion on the matter holds weights.
Tui plz.
Yes I understand main board rules, but I assume the quarterlies include operating metrics (volume) as the bare minimum for NXT. What is interesting is that PEB does not do quarterly updates (volume/sales) but companies on the NXT will be rquired to?
This should be a signal for PEB to release their quarterly metrics so we can track them better. I see no reason for the less regulated companies on the NXT to update on financial metrics more than a main board company. Before we get a string of email from MAC etc this is how I interpret the new rules and for companies that do not report their volume metrics each quarter this should force them to.
Here's a few to start with, from all over the world. Negligence is negligence. If using CXBladder is negligent then the doctor is covered. The propositions you make are becoming more and more fanciful.
http://www.vero.com.au/vero/sites/de...cy-wording.pdf
http://www.dualaustralia.com.au/file...ce_Wording.pdf
http://www.hiscoxbroker.co.uk/shared...-prods-ins.pdf
http://www.agdore.com/assets/documen...al_UK_2013.pdf
http://www.willis.com/Sites/Canada/D..._LIABILITY.pdf
http://www.irda.gov.in/ADMINCMS/cms/...ALPRACTICE.pdf
http://www.teamcare.com.au/Include/E....asp?FileId=82
http://www.mdanational.com.au/media/...ding%20v.8.pdf
http://www.macqund.com.au/downloads/...ing-MUML11.pdf
http://www.woodina.com.au/sites/defa...ding_09_12.pdf
The quarterly updates have to include volume metrics and these are crucial for any investor to know. If people dont see the contradiction that a main board company can hold out for 6 months to file the statutory half years accounts this leaves an investor in limbo for 3 extra months. I know which I prefer.
Was back in May, happy to discuss on the SUM thread;
http://www.sharetrader.co.nz/showthr...old#post482182
I must have been sleeping for months, woke up today to read the NBR Market Close for yesterday: 'Pacific Edge, the Dunedin-based biotech company, declined 2.3 percent to $5.00.'
Best news I've read all year!
They know something we don't know. And I like it.
Invisible blood in urine may indicate bladder cancer
http://www.exeter.ac.uk/news/feature...408171_en.html
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians.
and
Early diagnosis is crucial to have the best chance of successfully treating bladder cancer. The three-quarters of patients who are diagnosed early have much better outcomes than those whose disease is diagnosed late. Anything we can do to boost early detection is crucial to help save lives.”
We have just the test for you...:)
If you are in the high risk category, early screening as with other Cancers.. ?
thats easy. A national screening programme for "everyone", say, once every 12 months. Paid for from the massive savings on late diagnosis costs.
semi T-in-C, but might stimulate some conversation about CxBladder, rather than minutea detail for sales reporting every quarter, misleading newspaper reports, and Crim.Con and dirty politics
Moosie, there's your answer, dipstickQuote:
A urine dipstick test for haematuria is a relatively common occurrence in primary care. Management is determined by the presence of associated symptoms, risk factors for malignancy and additional investigations to identify an urological or nephrological cause.
:D
For what its worth, i do some training for Drs so asked the urologists
"...See you at 3.30 on Wednesday .I saw some interesting stuff about CxBladder .
Do you use that test ?"
reply
Yes, it is a great test that has taken over urine cytology. Xxxxxxx in particular uses it a lot for his patients."
Back to what's important in the short term. More interesting than all this chatter about what may happen in 5 years time. Todays share price is the important thing
The squiggly line on the chart has started turned down Hung in there at 80 but some small trades bailed at the close at 79
Doesn't look like that 90/100 this time around.
Will see what happens tomorrow morning. If looking a bit weak will take the 13%/14% profit this time around. Hope more liquidity than today. Always another go from sub 70 methinks .... sometime
Do you think PEB will revisit Sub 70?.......PEB chart is the best it has looked since March....The double bottom pattern seems confirmed when 75c bull/bear line was cracked.....A bit early yet to be sure (still could get a confirmation failure)..but at the moment the Bear cycle looks to be done and dusted
Large order at 80c placed 2.30ish. Someone likes PEB :P
Boys and girls backing 80 cents as the new supp. Thin asks - IMHO. Unless someone is short trading and looking to make a quick buck or two from previous weeks.